Resverlogix Corp. Market Cap ($18.68 Million)
Market Cap & Net Worth: Resverlogix Corp. (RVX)
Resverlogix Corp. market cap. Resverlogix Corp. (TO:RVX) has a market capitalization of $18.68 Million (CA$25.82 Million) as of November 4, 2026. Listed on the TO stock exchange, this Canada-based company holds position #25175 globally and #965 in its home market, demonstrating a -16.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Resverlogix Corp.'s stock price CA$0.08 by its total outstanding shares 344286709 (344.29 Million). Also see Resverlogix Corp. (RVX) cash conversion ratio for how efficiently the company converts equity into cash flow.
Resverlogix Corp. Market Cap History (2015–2026)
Resverlogix Corp. market cap history from 2015 to 2026. Data shows change from $433.35 Million to $18.68 Million (-24.24% CAGR). Check RVX stock price and chart for real-time trading data and today's change.
Resverlogix Corp. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Resverlogix Corp.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore RVX net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RVX by Market Capitalization
Companies near Resverlogix Corp. in the global market cap rankings as of November 4, 2026. Also see Resverlogix Corp. assets under control for a full breakdown of the balance sheet.
Key companies related to Resverlogix Corp. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Resverlogix Corp. (2015–2026)
Market capitalization of Resverlogix Corp. from 2015 to today. Between 2015 and today, Resverlogix Corp.'s market cap moved from $433.35 Million to $ 18.68 Million, with a yearly change of -24.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$18.68 Million | -25.00% |
| 2025 | CA$24.91 Million | +66.67% |
| 2024 | CA$14.94 Million | -14.29% |
| 2023 | CA$17.43 Million | -50.00% |
| 2022 | CA$34.87 Million | -72.55% |
| 2021 | CA$127.02 Million | -45.74% |
| 2020 | CA$234.11 Million | -23.58% |
| 2019 | CA$306.33 Million | -62.61% |
| 2018 | CA$819.38 Million | +60.49% |
| 2017 | CA$510.56 Million | +20.59% |
| 2016 | CA$423.39 Million | -2.30% |
| 2015 | CA$433.35 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Resverlogix Corp. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.68 Million USD |
| MoneyControl | $18.68 Million USD |
| MarketWatch | $18.68 Million USD |
| marketcap.company | $18.68 Million USD |
| Reuters | $18.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID… Read more